What AIMM Therapeutics does

AIMM Therapeutics, now operating as Kling Biotherapeutics BV, is a clinical-stage privately held biotechnology company headquartered in Amsterdam, the Netherlands. The company develops antibody-based therapeutics through a proprietary patient-derived B cell discovery platform, designed to identify novel therapeutic targets and corresponding human antibody binders directly from patients exhibiting exceptional clinical responses. Its core offering centers on two fully owned platform technologies: Kling-Select, a clinically validated B cell immortalization method that enables simultaneous discovery of novel targets and fully human antibodies (notably credited with the discovery of nirsevimab/Beyfortus, a marketed RSV antibody estimated to be a billion-dollar-plus product, plus neutralizing antibodies for Covid and Influenza); and Kling-Evolve, an ex vivo affinity maturation technology used to evolve B cell clones for affinity/selectivity improvement or rapid response to emerging viral variants.

Kling Biotherapeutics is progressing an internal oncology pipeline led by KBA1412, a first-in-class CD9 antibody currently in a Phase 1 clinical trial. Additional pipeline assets have emerged from applying Kling-Select to peripheral and tumor-infiltrating B cells from cancer patients, generating a portfolio of novel and selective target-antibody pairs. The company operates as a pre-commercial R&D organization with no disclosed product revenue, monetizing through licensing and partnership economics at the platform or asset level (no pricing or revenue mechanics are publicly disclosed). It is led by Tim Wright (Chairman, General Partner at Time BioVentures), D.A. Wallach (Director, Time BioVentures) and CSO Stefano Gulla, with implied venture backing from Time BioVentures. The company serves pharmaceutical partners, healthcare providers, and ultimately patients in oncology and infectious disease indications across the EMEA market.

Name

AIMM Therapeutics

Legal name

Kling Biotherapeutics BV

Website

https://aimmtherapeutics.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Kling Biotherapeutics (formerly AIMM Therapeutics) is a clinical-stage Amsterdam biotech that discovers antibody therapeutics from patient-derived B cells using its proprietary Kling-Select and Kling-Evolve platforms, with lead asset KBA1412 (anti-CD9) in Phase 1 oncology trials.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Antibody Therapeutics Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Monoclonal antibody discovery
• B cell immortalization
• Antibody therapeutics development
• Oncology pipeline programs
• Clinical-stage biotechnology

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Core offering

AIMM Therapeutics (operating as Kling Biotherapeutics) develops antibody-based therapeutics using its proprietary B cell immortalization platform, Kling-Select, which enables the simultaneous discovery of novel therapeutic targets and identification of fully human antibodies from patient-derived B cells. Its second platform, Kling-Evolve, performs ex vivo affinity maturation to optimize antibody affinity, selectivity, and responsiveness to emerging viral variants. The company applies these platforms to build and progress an internal pipeline of oncology and infectious disease antibody programs, including lead candidate KBA1412, a first-in-class CD9 antibody currently in Phase 1 clinical trials.

Product overview

Kling Biotherapeutics is a clinical-stage privately held biotech company offering a unified platform approach for antibody-based therapeutic discovery. The company's core offering consists of two proprietary platform technologies: Kling-Select (B cell immortalization for simultaneous target and antibody discovery) and Kling-Evolve (ex vivo affinity maturation for antibody optimization). These platforms work together to enable unbiased identification of novel therapeutic targets and unique epitopes inaccessible to traditional approaches. The company is progressing a pipeline of oncology programs led by KBA1412, a first-in-class CD9 antibody in Phase 1 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• Kling-Select: Fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses.
• Kling-Evolve

Products and services

• Kling-Select Fully-owned and clinically-validated B cell immortalization technology enabling simultaneous discovery of novel therapeutic targets and identification of fully human antibody binders from patient-derived B cells, with demonstrated applications in oncology and infectious disease (RSV, Covid, Influenza). Intended for biopharma partners seeking differentiated antibody candidates and targets.
• Kling-Evolve Ex vivo affinity maturation technology that enables rapid evolution of B cell clones against targets of interest, used to engineer neutralizing antibodies against emerging viral variants and to improve affinity and selectivity of oncology antibody assets. Intended for biopharma partners and internal pipeline optimization.
• KBA1412 First-in-class CD9 antibody and the company's lead clinical oncology asset, currently being evaluated in a Phase 1 clinical trial. Aimed at oncology indications where CD9-targeted therapy represents a novel mechanism.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Emerging players

• MacroGenics: MacroGenics develops antibody-based therapeutics including bispecifics, with proprietary DART platform. Comparable as a clinical-stage antibody platform company developing oncology biologics, similar to Kling's CD9 program.
• Harbour BioMed: Harbour BioMed is a clinical-stage antibody therapeutics company with discovery platforms (e.g., H2L2, HCAb) generating novel antibodies. Comparable as a platform-driven, clinical-stage antibody company with proprietary discovery technology.
• Arsanis: Arsanis (and successor entities) focused on monoclonal antibody therapeutics for infectious diseases, including RSV. This is a partially overlapping peer in the infectious-disease antibody space where Kling has demonstrated capability.

Broad incumbents

• Genmab: Genmab is a leading commercial-stage antibody therapeutics company with proprietary platforms (e.g., DuoBody bispecifics). It is a comparable antibody-focused biotech with much greater scale, relevant for benchmarking platform-to-product translation potential.
• AstraZeneca: AstraZeneca is the developer and commercializer of nirsevimab/Beyfortus, the antibody originally discovered using Kling's B cell platform. AZ represents the most direct validation of Kling's historical technology output.
• Regeneron Pharmaceuticals: Regeneron is a major antibody therapeutics company with its own B cell and VelocImmune platforms. It represents a direct benchmark for what a fully-integrated, successful antibody-discovery platform can achieve commercially.

Direct peers

• Atreca: Atreca develops antibody therapeutics using immune response interrogation of patients, similar to Kling's B cell-based discovery. Both companies use patient-derived samples to identify novel targets and antibody binders, making them directly comparable platform peers.
• Adimab: Adimab operates a proprietary antibody discovery and optimization platform serving pharma partners. While yeast-based rather than B cell-based, both companies compete in the differentiated antibody discovery space with platform-based licensing business models.

Others

• Distributed Bio: Distributed Bio (acquired by Charles River) provides antibody discovery and engineering services including B cell screening. Comparable as an adjacent, platform-oriented antibody discovery services provider in the broader ecosystem.

Regional players

• Merus: Merus is a Netherlands-based clinical-stage biotech developing bispecific and other therapeutic antibodies. Its Dutch HQ and clinical-stage antibody focus make it a strong regional comparison for Kling Biotherapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aimm-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIMM Therapeutics